In December 2019, the FDA approved olaparib as a treatment with germline BRCA-mutated metastatic pancreatic cancer after successful treatment with chemotherapy. BRCA mutations are associated with higher risk of developing breast and ovarian cancer, as well as prostate cancer and pancreatic cancer. Olaparib has already been approved in breast and ovarian cancer. In the POLO… Read more »
